Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Details
Publication Year 2024-09-03,Volume 30,Issue #17,Page 3788-3797
Journal Title
Clinical Cancer Research
Publication Type
Research article
Abstract
PURPOSE: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study. EXPERIMENTAL DESIGN: Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1). RESULTS: KRAS G12C ctDNA was detectable from plasma samples in 72.9% (43/59) and 92.6% (50/54) of patients with non-small cell lung cancer and colorectal cancer, respectively, the majority of whom were eligible for study participation based on a local test detecting the KRAS G12C mutation in tumor tissue. Baseline ctDNA tumor fraction was associated with tumor type, disease burden, and metastatic sites. A decline in ctDNA level was observed as early as cycle 1 day 15. Serial assessment showed a decline in ctDNA tumor fraction associated with response and progression-free survival. Except for a few cases of KRAS G12C sub-clonality, on-treatment changes in KRAS G12C variant allele frequency mirrored changes in the overall ctDNA tumor fraction. CONCLUSIONS: Across tumor types, the KRAS G12C mutation likely represents a truncal mutation in the majority of patients. Rapid and deep decline in ctDNA tumor fraction was observed in patients responding to divarasib treatment. Early on-treatment dynamics of ctDNA were associated with patient outcomes and tumor response to divarasib treatment.
Publisher
American Association for Cancer Research
Keywords
Humans; *Circulating Tumor DNA/genetics/blood; *Proto-Oncogene Proteins p21(ras)/genetics; *Mutation; Female; Male; Middle Aged; Aged; *Biomarkers, Tumor/genetics; Neoplasms/genetics/drug therapy/pathology/blood; Prognosis; Adult; Genetic Heterogeneity; Treatment Outcome; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung/genetics/drug therapy/pathology/blood
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1158/1078-0432.Ccr-24-0255
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-10 04:41:09
Last Modified: 2024-09-10 04:41:22

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙